From the approval of postbiotics for use in health supplements in India to Blackmores' NPD plans and China's approval of human milk oligosaccharides (HMOs) for use in infant formula, here are the most-read stories in October 2023.
Kyowa Hakko Bio, a subsidiary firm of Kirin, says its postbiotics is now approved for use in general foods and health supplements in India.
Blackmores is set to ramp up advertising to boost brand awareness in China and Indonesia, while also formulating new products with Kirin’s ingredients post the Japanese giants acquisition of the firm.
Human milk oligosaccharides (HMOs) are now officially permitted for use in China’s infant formula, with two multinationals, namely IFF and dsm-firmenich, as well as local dairy giant Mengniu, announcing that they have received approvals in the past week.
Swisse is launching its first “assessed listed” complementary medicine – a krill oil product for individuals suffering from mild to moderate osteoarthritis – next year in the Australian market.
An artificial intelligence (AI) model has been developed to identify new active ingredients in botanicals that could be used to develop new types of health functional foods (HFF) in South Korea.
While dairy is the basis of protein nutrition, the use of plant-based and precision fermented protein is bound to increase in products such as infant formula, healthy ageing, and sports nutrition, says dairy multinational firm Friesland Campina.
Global megabrand Suntory has highlighted consumer confusion and production time as some of the key challenges standing in the way of achieving ‘full personalisation’ in the nutrition and food manufacturing spaces.
The health and nutrition industry has a vast opportunity to meet women’s health needs beyond fertility and menopausal concerns, with experts believing there is still a huge gap in the range of products targeted at women’s wellbeing holistically.
Malaysia’s health ministry has issued an advisory on oral aloe vera products and its alleged links with kidney-related adverse reactions.
It is more important to focus on providing the best benefits, and not fall into the trap of innovating with new ingredients for the novelty factor, when developing new nutrition products for infants, says the global R&D head for VMS / Nutrition Health of Bayer's Consumer Health Division.
